EDROPHONIUM CHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Edrophonium Chloride, and when can generic versions of Edrophonium Chloride launch?
Edrophonium Chloride is a drug marketed by Hospira and Watson Labs and is included in three NDAs.
The generic ingredient in EDROPHONIUM CHLORIDE is edrophonium chloride. There are three drug master file entries for this compound. Additional details are available on the edrophonium chloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EDROPHONIUM CHLORIDE?
- What are the global sales for EDROPHONIUM CHLORIDE?
- What is Average Wholesale Price for EDROPHONIUM CHLORIDE?
Summary for EDROPHONIUM CHLORIDE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 89 |
| DailyMed Link: | EDROPHONIUM CHLORIDE at DailyMed |
Medical Subject Heading (MeSH) Categories for EDROPHONIUM CHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for EDROPHONIUM CHLORIDE
US Patents and Regulatory Information for EDROPHONIUM CHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | EDROPHONIUM CHLORIDE | edrophonium chloride | INJECTABLE;INJECTION | 040131-001 | Feb 24, 1998 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Labs | EDROPHONIUM CHLORIDE | edrophonium chloride | INJECTABLE;INJECTION | 040044-001 | Mar 20, 1996 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Labs | EDROPHONIUM CHLORIDE PRESERVATIVE FREE | edrophonium chloride | INJECTABLE;INJECTION | 040043-001 | Mar 20, 1996 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
